REDWOOD NEURO INC.
Democratizing Early Detection and Longitudinal Monitoring of Alzheimer's Disease: An Ultra-Sensitive Blood-Based Assay
Democratizing Early Detection and Longitudinal Monitoring of Alzheimer's Disease: An Ultra-Sensitive Blood-Based Assay is a funding opportunity from REDWOOD NEURO INC., up to 506061, closing August 31, 2026.
Aug 31, 2026
(31d left)Overview
PROJECT SUMMARY/ABSTRACT Redwood Neuro aims to revolutionize Alzheimer’s Disease (AD) diagnostics through the development of the SiMoLiSA platform, a pioneering technology designed to deliver a detection capability previously only achievable through high- end single molecule counting technologies. This innovative…